Skip to main content
SpringerLink
Log in

PsA: Ustekinumab wirkt bei TNF-Therapie-Versagen

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

Seine Wirksamkeit gegen PsA hat der Antikörper Ustekinumab bereits in der PHASE-3-Studie PSUMMIT 1 gezeigt. In PSUMMIT 2 wurde der Interleukin-12/23-Inhibitor nun bei Patienten mit TNF-alpha-Inhibitor-Vorbehandlung getestet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Ritchlin C et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy. ARD 2014 Jan 30

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Beate Schumacher

Authors
  1. Beate Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schumacher, B. PsA: Ustekinumab wirkt bei TNF-Therapie-Versagen. hautnah dermatologie 30, 18 (2014). https://doi.org/10.1007/s15012-014-1743-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-014-1743-2

Search

Navigation